TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered
together with ruxolitinib in patients with myeloproliferative neoplasms (specifically:
polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.